Charles River Laboratories International, Inc. $CRL Stock Holdings Lessened by Gotham Asset Management LLC

Gotham Asset Management LLC cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 289,516 shares of the medical research company’s stock after selling 26,239 shares during the period. Gotham Asset Management LLC’s holdings in Charles River Laboratories International were worth $57,753,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in CRL. Massachusetts Financial Services Co. MA purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $176,478,000. Victory Capital Management Inc. raised its holdings in shares of Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Charles River Laboratories International by 1,491.1% during the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after purchasing an additional 575,039 shares during the last quarter. National Bank of Canada FI boosted its position in Charles River Laboratories International by 117.7% during the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after purchasing an additional 511,901 shares during the last quarter. Finally, Norges Bank purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $96,765,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their price target for the stock from $167.00 to $219.00 in a research note on Friday, May 29th. Robert W. Baird set a $213.00 price objective on Charles River Laboratories International in a report on Friday, May 8th. UBS Group raised their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, TD Cowen dropped their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $211.00.

Charles River Laboratories International Price Performance

NYSE CRL opened at $182.97 on Thursday. The stock has a 50-day simple moving average of $174.31 and a 200 day simple moving average of $182.64. Charles River Laboratories International, Inc. has a twelve month low of $143.06 and a twelve month high of $228.88. The stock has a market capitalization of $8.81 billion, a PE ratio of -48.66, a P/E/G ratio of 2.11 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. During the same period last year, the business posted $2.34 EPS. The business’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.